Fractionated Intermediate‐Dose Etoposide Plus G‐ CSF for Peripheral Blood Stem Cell Mobilization in Patients With Lymphoma and Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Prospective Observational Study
Journal of Clinical Apheresis · 2026
DOI: 10.1002/jca.70183 ↗At a glance
Beobachtungsstudie in Journal of Clinical Apheresis, 2026. Written by Yoo Jin Lee and 6 co-authors. Institution: Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea. Major MEDLINE topics: Granulocyte Colony-Stimulating Factor, Etoposide, Hematopoietic Stem Cell Mobilization, Multiple Myeloma. 20 references. Funded by: Ulsan University Hospital Research Grant (UUH-2023-11), DKSH Korea.
Topics: Mobilisation
Abstract (original language)
Efficient and safe mobilization of peripheral blood CD34 + stem cells is essential for successful autologous stem cell transplantation (ASCT) in patients with lymphoid malignancies. However, current mobilization strategies are often limited by suboptimal yield, significant toxicity, or high cost. We conducted a prospective observational study including 59 patients with lymphoma or multiple myeloma undergoing ASCT. Patients received fractionated intermediate‐dose etoposide (175 mg/m 2 twice on days 1 and 2) followed by granulocyte colony‐stimulating factor (G‐CSF, 10 μg/kg daily). Mobilization efficacy, safety profile, and subsequent transplantation outcomes were evaluated. Successful mobilization (≥ 2 × 10 6 CD34+ cells/kg) was achieved in 96.6% of patients within three days of apheresis. The median CD34 + cell yield was 5.35 × 10 6 CD34+ cells/kg on the first day. Notably, 61.0% and 49.2% of patients collected ≥ 4 × 10 6 and ≥ 6 × 10 6 CD34 + cells/kg on the first day, respectively. Despite frequent grade 3–4 cytopenias, clinically significant complications were limited, with febrile neutropenia occurring in 16.9% of patients and no treatment‐related mortality (TRM). All patients achieved neutrophil and platelet engraftment. Fractionated intermediate‐dose etoposide combined with G‐CSF achieved a high mobilization success rate, with most patients requiring a limited number of apheresis sessions and no TRM.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea.
- Department of Laboratory Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea.
- Department of Pathology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea.
ORCID profiles: Yoo Jin Lee, HeeJung Cha, Jae-Cheol Jo
Funding
- Ulsan University Hospital Research Grant (UUH-2023-11)
- DKSH Korea
Cite
APA
Lee, Y. J., Park, S. H., Kim, Y., Lim, J. H., Kim, H. K., Cha, H., & Jo, J. C. (2026). Fractionated Intermediate‐Dose Etoposide Plus G‐ CSF for Peripheral Blood Stem Cell Mobilization in Patients With Lymphoma and Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Prospective Observational Study. Journal of Clinical Apheresis. https://doi.org/10.1002/jca.70183
Vancouver
Lee YJ, Park SH, Kim Y, Lim JH, Kim HK, Cha H, et al. Fractionated Intermediate‐Dose Etoposide Plus G‐ CSF for Peripheral Blood Stem Cell Mobilization in Patients With Lymphoma and Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Prospective Observational Study. Journal of Clinical Apheresis. 2026. doi:10.1002/jca.70183
BibTeX
@article{Lee2026,
author = {Lee, Yoo Jin and Park, Sang Hyuk and Kim, Youjin and Lim, Ji-Hun and Kim, Hyun-Ki and Cha, HeeJung and Jo, Jae-Cheol},
title = {Fractionated Intermediate‐Dose Etoposide Plus G‐ CSF for Peripheral Blood Stem Cell Mobilization in Patients With Lymphoma and Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Prospective Observational Study},
journal = {Journal of Clinical Apheresis},
year = {2026},
doi = {10.1002/jca.70183}
}
EUVIMED